At a glance
ClinicalIndex Comparison Record- ✓Hospitalized patients with documented S. aureus infection (community or hospital-acquired) at Ann Arbor VA Medical Center, University of Michigan Medical Center, or St. Joseph Mercy Hospital, Ypsilanti
- ✓Able to provide written informed consent (patient, guardian, or next of kin)
- ✕Unable to cooperate with treatment or follow-up
- ✕Not likely to survive beyond one month or transferred to another acute care hospital
- ✕Requiring concurrent treatment with rifampin
- ✕Known hypersensitivity to mupirocin ointment or polyethylene glycol base
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intermittent Mupirocin to Prevent Staphylococcal Infection
In Brief
A Phase 4 clinical trial evaluating Mupirocin Ointment [Treatment] and Polyethylene Glycol Ointment [Placebo] for Staphylococcal Infections. Completed, enrolled 146 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment \[Treatment Arm\] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment \[Placebo Arm\].
Study Details
Timeline
Interventions
The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.